Esperion Therapeutics (ESPR) Cash from Financing Activities (2012 - 2026)

Esperion Therapeutics has reported Cash from Financing Activities for 15 years, with the latest figure at $16.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 316.23% year-over-year to $16.2 million; the trailing twelve-month figure through Mar 2026 stood at $59.9 million (up 615.41% YoY), and the FY2025 full-year result was $36.2 million, down 58.16% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $16.2 million, down from $30.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $90.6 million in Q1 2024, with the low at -$30.4 million in Q4 2022.
• Historically, Cash from Financing Activities has averaged $13.1 million across 5 years, with a median of $4.5 million in 2023.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 3546.52% — and 2024, when it plunged 3811.12%.
• Esperion Therapeutics' Cash from Financing Activities stood at -$30.4 million in 2022, then surged by 114.73% to $4.5 million in 2023, then jumped by 682.73% to $35.0 million in 2024, then declined by 13.81% to $30.2 million in 2025, then sank by 46.23% to $16.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $16.2 million (Q1 2026), $30.2 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.